

Clinical phase I development for SCLC and GIST using antibody-drug conjugate targeting c-Kit

Novelty Nobility Inc.
NOVELTY  NOBILITY

| ONCOLOGY | Phase 1 |
|--------------------------|---|
| Product Type | BIO-Antibody-ADC |
| Indication | SCLC, GIST |
| Target | c-Kit |
| MoA(Mechanism of Action) | <ul style="list-style-type: none"> • Binds to c-Kit overexpressed on SCLC and GIST tumor • Competes with SCF to inhibit c-Kit signaling pathways • Readily internalized and releases payload (MMAE) • Induces cell cycle arrest and apoptosis • Bystander effect |
| Competitiveness | <ul style="list-style-type: none"> • Strong efficacy as a single agent <i>in vitro</i> and <i>in vivo</i> • Good candidate for rational combination with ICI or TKI for improved anti-cancer efficacy • Targets regardless of c-Kit mutations that prevalently emerge with c-Kit targeting TKI treatments • Good safety profile in NHP repeat tox study |
| Development Stage | Phase 1a |
| Route of Administration | Intravenous (<i>i.v.</i>) |